The modified Friedreich’s Ataxia Rating Scale (mFARS) is a clinically validated set of assessments that measures Friedreich’s ataxia (FA) progression and its impact on a patient’s ability to perform activities of daily living.1

In addition to evaluating disease progression, changes to mFARS scores over time have been typically accepted as an endpoint in clinical trials for potential new FA treatments.1

Patient mFARS Composite Scores Will Typically Increase ~2 Points Per Year2

The mFARS identifies milestones in clinical outcome measures of FA progression.

A multicenter natural history study evaluated 812 patients diagnosed with FA annually, using multiple tests, including FARS and mFARS. The mean length of GAA triplet repeat was 636 and mean age of onset was 13.7 years.2

*Noted ages are at baseline.

The 4 mFARS Components

The mFARS includes traditional elements of a neuromuscular assessment that specifically focus on a patient’s disabilities.

Watch Sub Subramony, MD, Neurology, University of Florida Health, discuss the clinical relevance of mFARS scores for patient mobility and independence.

mFARS

An overview of the mFARS assessments to measure disease progression and help predict the pace of future progression, with the goal of supporting independence as long as possible.

Bulbar Function

An important measure of the strength and volume of coughing and clarity of speech.

Upper Limb Coordination

Key assessments for motor abilities related to tremors, fine motor coordination, and steadiness of hands and arms.

Lower Limb Coordination and Upright Stability

Two essential assessments of sitting, standing, and walking, focusing on coordination of legs and feet, status of ambulation, and ability to coordinate voluntary movements.

Stay Connected

Sign up to receive the latest news and resources for FA.

I authorize Reata Pharmaceuticals, Inc. (Reata), to send me emails regarding Friedreich's ataxia, genetic testing, and other informational materials. I understand that I may revoke this authorization and choose not to receive information from Reata by clicking the “unsubscribe” link provided in emails I receive from Reata. I have read and understand Reata’s Privacy Notice.

References: 1. Rummey C, Corben LA, Delatycki MB, et al. Psychometric properties of the Friedreich Ataxia Rating Scale. Neurol Genet. 2019;5(6):371. 2. Patel M, Isaacs CJ, Seyer L, et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann Clin Transl Neurol. 2016;3(9):684-694.

You are now leaving ThinkFA.com

You are now leaving ThinkFA.com. Links are provided as a convenience and for general informational purposes only. Reata does not control the site you are going to. It is recommended you carefully review the terms of use and privacy statement of any other sites. You are solely responsible for your interactions.

Go Back Leave

You are now leaving ThinkFA.com

You will be going to ConnectFA.com, a Reata website for patients and caregivers. ConnectFA.com contains links that are provided as a convenience and for general informational purposes. These links are not controlled by Reata. It is recommended you carefully review the terms of use and privacy statements of any other sites. You are solely responsible for your interactions.

Go Back Leave